Brain Research Institute, Department of Neurosurgery, Yonsei University College of Medicine, Seoul, Korea.
Department of Neurology, Yonsei University College of Medicine, Seoul, Korea.
Transl Neurodegener. 2021 Nov 5;10(1):44. doi: 10.1186/s40035-021-00269-8.
Focused ultrasound (FUS)-mediated blood-brain barrier (BBB) opening has shown efficacy in removal of amyloid plaque and improvement of cognitive functions in preclinical studies, but this is rarely reported in clinical studies. This study was conducted to evaluate the safety, feasibility and potential benefits of repeated extensive BBB opening.
In this open-label, prospective study, six patients with Alzheimer's disease (AD) were enrolled at Severance Hospital in Korea between August 2020 and September 2020. Five of them completed the study. FUS-mediated BBB opening, targeting the bilateral frontal lobe regions over 20 cm, was performed twice at three-month intervals. Magnetic resonance imaging, F-Florbetaben (FBB) positron emission tomography, Caregiver-Administered Neuropsychiatric Inventory (CGA-NPI) and comprehensive neuropsychological tests were performed before and after the procedures.
FUS targeted a mean volume of 21.1 ± 2.7 cm and BBB opening was confirmed at 95.7% ± 9.4% of the targeted volume. The frontal-to-other cortical region FBB standardized uptake value ratio at 3 months after the procedure showed a slight decrease, which was statistically significant, compared to the pre-procedure value (- 1.6%, 0.986 vs1.002, P = 0.043). The CGA-NPI score at 2 weeks after the second procedure significantly decreased compared to baseline (2.2 ± 3.0 vs 8.6 ± 6.0, P = 0.042), but recovered after 3 months (5.2 ± 5.8 vs 8.6 ± 6.0, P = 0.89). No adverse effects were observed.
The repeated and extensive BBB opening in the frontal lobe is safe and feasible for patients with AD. In addition, the BBB opening is potentially beneficial for amyloid removal in AD patients.
聚焦超声(FUS)介导的血脑屏障(BBB)开放已在临床前研究中显示出清除淀粉样斑块和改善认知功能的疗效,但在临床研究中很少报道。本研究旨在评估重复广泛 BBB 开放的安全性、可行性和潜在益处。
在这项开放标签、前瞻性研究中,韩国 Severance 医院于 2020 年 8 月至 9 月期间招募了 6 名阿尔茨海默病(AD)患者。其中 5 名完成了研究。FUS 介导的 BBB 开放,靶向双侧额叶区域超过 20cm,在 3 个月的间隔内进行两次。在程序前后进行磁共振成像、F-Florbetaben(FBB)正电子发射断层扫描、照顾者管理的神经精神疾病问卷(CGA-NPI)和全面的神经心理学测试。
FUS 靶向的平均体积为 21.1±2.7cm,BBB 开放在 95.7%±9.4%的靶向体积内得到确认。与术前相比,术后 3 个月时额叶到其他皮质区域的 FBB 标准化摄取比值略有下降(-1.6%,0.986 与 1.002,P=0.043)。与基线相比,第二次手术后 2 周时的 CGA-NPI 评分显著下降(2.2±3.0 与 8.6±6.0,P=0.042),但在 3 个月后恢复(5.2±5.8 与 8.6±6.0,P=0.89)。未观察到不良反应。
AD 患者额叶的重复和广泛 BBB 开放是安全可行的。此外,BBB 开放可能有益于 AD 患者的淀粉样蛋白清除。